Business
ImmuCell to Announce Unaudited Financial Results for Second Quarter of 2020
Conference Call Scheduled for Thursday, August 13, 2020 at 9:00 AM ET PORTLAND, Maine, Aug. 06, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC)
About this update from Immucell Corporation
[{"type":"text","content":"Conference Call Scheduled for Thursday, August 13, 2020 at 9:00 AM ET\nPORTLAND, Maine, Aug. 06, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef calves, will report unaudited financial results for the quarter ended June 30, 2020 after the market closes on Wednesday, August 12, 2020. \n The Company has scheduled a conference call the next morning, Thursday, August 13, 2020, at 9:00 AM ET to review the results. Interested parties can access the conference call scheduled by the Company to review these results by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET on Thursday, August 13, 2020. A teleconference replay of the call will be available for seven days at (877) 344-7529 (toll free) or (412) 317-0088 (international), utilizing confirmation #10145671. The Company expects to file its Quarterly Report on Form 10-Q on Wednesday, August 12, 2020. Investors are encouraged to review the Company’s updated Corporate Presentation slide deck that provides an overview of the Company’s business which will be posted under the “Investors” tab of the Company’s website at www.immucell.com after the market closes on Wednesday, August 12, 2020, or by request to the Company. About ImmuCell: ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically-proven and practical products that improve the health and productivity of dairy and beef calves. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is in the late stages of developing Re-Tain™, a novel treatment for subclinical mastitis without a milk discard requirement that provides an alternative to traditional antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com. Contact: Michael F. Brigham, President and CEO ImmuCell Corporation (207) 878-2770 Joe Diaz, Robert Blum and Joe Dorame Lytham Partners, LLC (602) 889-9700 [email protected] Cautionary Note Regarding Forward-Looking Statements (Safe Harbor Statement):This Press Release contains “forward-looking statements” within the meaning of Section 27A of the Se...